Phase 3 trial shows major survival benefit with tarlatamab in SCLC, according to Oncodaily item
An Oncodaily item headed with Anthony Letai's name reports that a phase 3 trial showed a major survival benefit with tarlatamab in small cell lung cancer (SCLC).
“Phase 3 Trial Shows Major Survival Benefit With Tarlatamab in SCLC”— Oncodaily
An item published by Oncodaily on 6 November 2026 reports that a phase 3 trial has shown a major survival benefit with tarlatamab in SCLC. The item is headed with the name of Anthony Letai.
The headline describes the survival benefit as "major". The source text available does not define that term or say how it was measured.
The item as provided contains no further detail. It does not name the trial, describe the patient population or comparator, give survival figures, or state where the results were published or presented. No journal is cited.
Because of this, the finding cannot yet be assessed beyond the headline claim. Readers will need the full trial report or the original post for the data behind the statement.
